Interventional radiology — the image-guided minimally invasive procedures from vascular access and embolization through tumor ablation, vertebroplasty, and peripheral vascular intervention — represents the highest-revenue procedural component of radiology, with the US Radiology Services Market reflecting IR as the commercially premium radiology market segment.

Oncologic interventional radiology — the thermal ablations (RFA, microwave ablation, cryoablation), transarterial chemoembolization (TACE), radioembolization (Y-90 SIRT), and tumor biopsy procedures — represent the most rapidly growing IR clinical and commercial segment. The growth of liver cancer, renal cell carcinoma, lung cancer, and bone metastases treatment through IR-guided ablation creating the expanding procedure market from the intersection of interventional radiology capability and oncology treatment needs.

Y-90 radioembolization (SIRT) — the Sirtex SIR-Spheres and Boston Scientific TheraSphere Y-90 microsphere liver tumor treatment — represents the premium IR oncology treatment combining interventional technique with radiation oncology. The approximately twenty-thousand annual US Y-90 procedures and significant international adoption creating the multi-hundred-million-dollar Y-90 market.

Peripheral arterial disease IR procedures — the balloon angioplasty, stenting, atherectomy, and drug-coated balloon treatments for peripheral artery disease — represent the high-volume vascular IR procedure market. The growing PAD burden from diabetes and smoking creating the structural demand for peripheral vascular intervention that IR specialists perform in competition with vascular surgery.

Do you think interventional radiology will achieve broad recognition as a distinct clinical specialty separate from diagnostic radiology, with dedicated IR residency pathways fundamentally changing the IR commercial and clinical market?

FAQ

What interventional radiology procedures generate the most revenue? Highest revenue IR procedures: Y-90 radioembolization (SIR-Spheres, TheraSphere — $15,000-25,000 technical component); complex peripheral vascular intervention (angioplasty plus stent — $8,000-15,000); IVC filter placement/retrieval; uterine fibroid embolization; percutaneous tumor ablation (RFA, microwave, cryoablation — $5,000-12,000); TACE (transarterial chemoembolization — $8,000-15,000); kyphoplasty; large bore access (TAVR support); combined professional plus technical billing; most IR procedures in hospital outpatient or ASC settings with significant facility fee component.

What is transarterial radioembolization (Y-90) for liver tumors? Y-90 SIRT (Selective Internal Radiation Therapy): microscopic resin (SIR-Spheres, Sirtex) or glass (TheraSphere, Boston Scientific) microspheres loaded with Y-90 beta emitter; injected through hepatic artery catheter; microspheres lodge in tumor microvasculature delivering high-dose radiation; indications: hepatocellular carcinoma (primary liver cancer); colorectal liver metastases (unresectable); technique: requires hepatic artery mapping (MAA planning scan), simulation dosimetry; outpatient procedure; typical survival benefit versus systemic chemotherapy in selected patients; commercial market: approximately $200-300 million US annually; growing from liver cancer incidence.

#USRadiology #InterventionalRadiology #Y90SIRT #IRprocedures #TumorAblation #PeripheralVascular